Precision Medicine Approach for Treating Advanced Sarcoma, Prostate, Breast, Ovarian, or Pancreatic Cancer

Sponsor: OHSU Knight Cancer Institute

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT06630325

Provider View

This clinical trial is exploring a precision medicine approach to treat advanced sarcoma, prostate, breast, ovarian, or pancreatic cancer. The study uses genetic and protein tests to understand how cancer changes and to find the best treatment options for each patient.

Patient Parameters

Program Overview

This study is testing a precision medicine approach called SMMART-ACT to treat advanced cancers like sarcoma, prostate, breast, ovarian, or pancreatic cancer. The approach involves using genetic and protein tests to understand how a patient's cancer changes and to identify effective treatments. A team of doctors and scientists reviews these test results to recommend personalized therapies. The study aims to see if this method can safely and effectively treat these cancers and improve patients' quality of life.

Description

The main goal of this study is to see if a precision medicine approach can help doctors choose personalized treatment plans for patients with advanced cancer. The study will also look at how safe and tolerable these treatments are, and whether they can improve survival rates and quality of life for patients.

Patients in the study will be assigned to one of 14 different treatment groups. Each group will receive a specific combination of medications, and patients may switch groups if their cancer progresses or if they experience unacceptable side effects.

For example, in one group, patients will take abemaciclib and gemcitabine, while in another group, they will take abemaciclib and pemetrexed. Other groups will receive different combinations of medications, such as olaparib and temozolomide, or gefitinib and carboplatin.

Throughout the study, patients will have regular blood tests and may undergo tumor biopsies to monitor their response to treatment. Prostate cancer patients will also have bone scans.

After completing the study treatment, patients will be followed up for 30 days, then every 3 months for a year, and every 6 months until year 5 to monitor their health and any long-term effects of the treatment.

Eligibility Criteria

Inclusion Criteria

  • Must be at least 18 years old and have advanced sarcoma, prostate, breast, ovarian, or pancreatic cancer.
  • Must provide a tumor sample for testing, unless a recent sample is available.
  • Must have a good performance status and a life expectancy of at least 6 months.
  • Must have tried at least one previous treatment for advanced cancer.
  • Must meet specific health criteria, including adequate blood counts and organ function.
  • Must not have more than one new treatment since the pre-screening biopsy.
  • Must not have any active infections or other serious health conditions that could interfere with the study.

Exclusion Criteria

  • Cannot have another active cancer that could affect the study results.
  • Cannot have brain or central nervous system metastases that are progressing or require immediate treatment.
  • Cannot be receiving other cancer treatments that could interfere with the study.
  • Cannot have untreated hepatitis C or other serious infections.
  • Cannot have severe heart conditions or other serious health issues.
  • Cannot be pregnant or breastfeeding, and must agree to use contraception if of childbearing potential.
  • Cannot have a history of severe allergies to study medications.
  • Prostate cancer patients with a specific type of bone scan result will be excluded.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.